Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing loaded with clinical data tables and dilution clauses can feel impossible. Prelude Therapeutics’ precision-oncology focus means every 10-K includes pages on SMARCA2 degrader chemistry, while each 8-K may reveal pivotal trial readouts that move the stock overnight. If you have ever hunted for cash-runway details or wondered whether a secondary offering is hiding in the footnotes, you know how complex Prelude’s disclosures can be.
Stock Titan turns that complexity into clarity. Our AI-powered summaries flag R&D spending spikes, translate technical risk factors, and surface Prelude Therapeutics SEC filings explained simply. Need the latest Prelude Therapeutics quarterly earnings report 10-Q filing or a concise view of revenue, burn rate and trial costs? It’s here, updated in real time as documents hit EDGAR. Track Prelude Therapeutics insider trading Form 4 transactions and receive Prelude Therapeutics Form 4 insider transactions real-time alerts before the market reacts. You’ll also find the full spectrum of documents—10-K, 10-Q, 8-K, S-3, S-8 and proxy materials—each with an AI summary that highlights what matters.
Looking for actionable insights? Compare segments with our Prelude Therapeutics earnings report filing analysis. Review executive pay in the Prelude Therapeutics proxy statement executive compensation section, or see confidence signals via Prelude Therapeutics executive stock transactions Form 4. We even decode material news with Prelude Therapeutics 8-K material events explained and offer a Prelude Therapeutics annual report 10-K simplified readout so you can spot clinical milestones, partnership terms and dilution risks in minutes—not hours.
Jane Huang, President and CMO of Prelude Therapeutics Inc (PRLD), reported transactions on
Prelude Therapeutics reported continued operating losses while advancing multiple oncology programs and managing liquidity constraints. For the six months ended June 30, 2025, the company recorded a $63.3 million net loss and had an accumulated deficit of $646.9 million. At June 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $77.3 million, but management states these funds are insufficient to cover at least the next twelve months absent additional financing, and substantial doubt exists about the company’s ability to continue as a going concern.
Operationally, R&D and G&A decreased year-over-year to $54.6 million and $12.2 million for the six months, respectively, as clinical expenses and stock-based compensation moderated. Key program milestones include ongoing Phase 1/2 activity for SMARCA2 degraders (PRT3789 and oral PRT7732) and collaborations with AbCellera and Merck. The company also received a Nasdaq bid price deficiency notice with an initial compliance period through September 23, 2025, and maintains a $400 million shelf registration and a $75 million sales agreement capacity that could support future financing.
Prelude Therapeutics furnished a press release disclosing its financial results for the three months ended June 30, 2025, which is attached to this report as Exhibit 99.1. Management also prepared investor presentation materials intended for use in investor presentations and attached those materials as Exhibit 99.2. The filing notes an interactive data file is included as Exhibit 104.
The report emphasizes that the press release and presentation are being furnished, not filed, and therefore are not incorporated by reference into the company’s other securities filings. The 8-K itself does not include the underlying financial figures in its body; readers must review Exhibit 99.1 for the detailed results. The form is signed on the company’s behalf by Bryant Lim, Chief Legal Officer, Corporate Secretary, and Chief Financial Officer.
FAQ
What is the current stock price of Prelude Therapeutics (PRLD)?
What is the market cap of Prelude Therapeutics (PRLD)?
